By using a combination of amrubicin or a pharmaceutically acceptable salt thereof with another medicament for treating lung cancer (irinotecan, vinorelbine, gemcitabine, etc.), it is intended to provide medicaments for treating lung cancer having an improved antitumor therapeutic effect on lung cancer and reduced side effects. Lung cancer can be effectively treated using these medicaments.